FY2024 EPS Estimates for PepGen Increased by Leerink Partnrs

PepGen Inc. (NASDAQ:PEPG) – Investment analysts at Leerink Partnrs raised their FY2024 earnings per share (EPS) estimates for shares of PepGen in a research report issued on Sunday, November 10th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will earn ($2.91) per share for the year, up from their previous forecast of ($3.37). The consensus estimate for PepGen’s current full-year earnings is ($2.99) per share. Leerink Partnrs also issued estimates for PepGen’s Q4 2024 earnings at ($0.74) EPS, Q1 2025 earnings at ($0.76) EPS, Q2 2025 earnings at ($0.80) EPS, Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.87) EPS, FY2025 earnings at ($3.27) EPS and FY2026 earnings at ($2.98) EPS.

A number of other analysts have also recently commented on PEPG. HC Wainwright reiterated a “buy” rating and issued a $26.00 target price on shares of PepGen in a research note on Friday, November 8th. Bank of America lowered shares of PepGen from a “buy” rating to a “neutral” rating and set a $12.00 price objective on the stock. in a report on Wednesday, July 31st. Finally, Wedbush cut their target price on PepGen from $19.00 to $12.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th.

PepGen Stock Performance

Shares of NASDAQ PEPG opened at $4.49 on Wednesday. PepGen has a fifty-two week low of $3.81 and a fifty-two week high of $19.30. The company has a market cap of $146.37 million, a PE ratio of -1.51 and a beta of 1.76. The business has a 50-day simple moving average of $8.12 and a two-hundred day simple moving average of $12.01.

Hedge Funds Weigh In On PepGen

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Acadian Asset Management LLC purchased a new stake in shares of PepGen in the 1st quarter valued at $30,000. Point72 DIFC Ltd acquired a new position in PepGen during the second quarter valued at $42,000. Allspring Global Investments Holdings LLC purchased a new stake in PepGen in the third quarter valued at $95,000. Renaissance Technologies LLC acquired a new stake in PepGen during the 2nd quarter worth about $192,000. Finally, Marshall Wace LLP acquired a new stake in PepGen during the 2nd quarter worth about $196,000. Institutional investors and hedge funds own 58.01% of the company’s stock.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.